



JPND


research

EU Joint Programme – Neurodegenerative Disease Research

EU Joint Programme - Neurodegenerative Disease Research

Adriana Maggi
Vice-Chair, JPND Executive Board
28/09/2011

Frequency of Neurodegenerative Diseases



From Rocca W et al, Eurodem



Alzheimer's disease in Europe


	Number of cases	Societal costs (€)
2010	6.000.000	72.000.000.000
2040	12.000.000	144.000.000.000



A major societal challenge
for the coming years



Research efforts are fragmented



Size of sphere proportional to funding








Taking the disease into account in all its dimensions

To mobilise the best researchers from all fields

To develop the sharing of best practices and know how

- | A scientific challenge
 - Genomics
 - Experimental models
 - Cell biology
 - ...
- | A medical challenge
 - Clinical research
 - Translational research
 - Therapeutics research
 -
- | An ethical and social challenge



EU Joint Programme on Neurodegenerative Disease Research (JPND)


is a Member States-led initiative to:

- Increase EU research capacity in neurodegenerative diseases
- Reduce fragmentation and unnecessary duplication of research
- Improve outcomes and care throughout Europe



Organisation

- **Management Board**
 - 23 countries represented
 - Mandated to act
- **Executive Board**
 - Chair: Philippe Amouyel (France)
 - Vice-Chair: Adriana Maggi (Italy)
 - Enda Connolly (Ireland)
 - Edvard Beem (The Netherlands)
 - Eckhart Curtius (Germany)
- **Scientific Advisory Board**
 - 15 Members (5 in each domain)
 - Chosen for scientific excellence




JPND – today



- Preparation of a European Strategic Research Agenda is underway including research mapping
 - Decisions on first priority areas imminent
- “National Strategic Agendas” being encouraged
- 2 call for proposals already launched:

Call Title	Number	Amount
Centre of Excellence Network (COEN) Initiative	6 Countries	€7 Million
Optimisation of biomarkers and harmonisation of their use between clinical centres	20 Countries	€15 Million



Towards Joint Programming in Research



Towards a common strategic research agenda for 2011



Strategic Research Agenda



The SRA – what is it?

- A holistic ‘roadmap’ for future EU-wide activity and investment
- not a review of the field, not a list of calls for proposals


Delivery of the SRA will take into account

- SAB recommendations – based upon outputs from 4 scientific/strategic workshops
- National and European research portfolios
- Broad consultation with stakeholder groups



Scope of the initiative

Focus on Three Domains



Building the SRA

Aim

- to identify research opportunities, gaps, barriers to progress
- to identify necessary infrastructures and technologies
- to identify priority research areas in the short and longer term
- to identify research requiring a cross-border approach
- to provide reports as a basis for stakeholder discussion

Timeline (2011)

- March – 3 thematic workshops (Paris, Madrid, London)
- April – preliminary reports for focussed stakeholder discussion
- May – workshop reports published and stakeholder meetings
- June – 4th ‘integrative’ prioritisation workshop (Rome)
- July – final workshop report published for consultation
- August – online consultation
- Sept 29th – MB discussion



What about stakeholders?

Key stakeholder groups for JPND

- Patients and Carers
- Healthcare professionals
- Policy makers
- Industry:
 - biopharma, biotech, diagnostics and devices, informatics, telemedicine, smart home technologies and other healthcare
- Research charities and other funders



JPND mapping exercise



Objective

- Map, and create a database of, research activity and resources relevant to neurodegenerative diseases across the 23 JPND countries and EC-funded projects

Aim of exercise

- To provide context for developing the SRA
- To provide a community resource
- To provide an updatable platform for other funding agencies



Mapping Exercise

Research activity

- programmes in basic, clinical and health care / social research
- other (smaller) research projects
- centres of excellence
- national research networks

Resources

- bioresources (DNA collections, tissue banks, cell and animal models)
- patient registers, clinical and population cohorts

Policy frameworks that underpin research


- for diagnosis, service provision and delivery
- policies or regulations relating to care home support
- education programmes for health professionals and carers




JPND mapping: 23rd August

- €1.57bn investment – 374 programmes, 1766 smaller projects
- 254 bioresources captured

Survey Section	Entries	Which represents:
Organisational Details	68	Organisations from 20 countries
Smaller Investments	59	€0.27 billion - 59 agencies from 18 countries + pan-Europe covering 1766 projects
Major Programmes	374	€1.3 billion - 40 funding agencies (13 countries + pan-European agencies)
Centres of Excellence	130	15 countries
Research networks	46	8 countries + pan-European networks
Population Cohorts	66	14 countries
Case Control Studies	22	9 countries
Disease Registers	20	8 countries + pan-European registries
DNA/Tissue Banks	76	14 countries
Animal Models	42	10 countries
Bio/Neuro Infrastructures	18	8 countries + 1 pan-European resource



ND research spend by disease



Implementation and test-case

- While waiting for SRA delivery, the SAB recommended launching rapid actions.
- "Neurodegenerative Diseases - a call for European research projects for the optimisation of biomarkers and harmonisation of their use between clinical centres"
- Launched by JPND on 13 May 2011
- 20 countries participating
- Commitment for 16 M€



Schedule for the call

- Provisional commitment: Jan 2011
- Final call text: Feb 2011
- Final commitment April 2011
(signature of a memorandum of understanding)
- Call published: 13 May 2011
- Deadline for proposal submission 5 Sept 2011
- Peer Review Panel meeting: Oct 2011
- Final funding decision: Nov 2011
- Project start (budget relevance): First quarter 2012



Other actions

- *Centres of Excellence Network in Neurodegeneration Research (COEN)* is considered part of JPND.
 - Germany, UK, Ireland, Canada, Belgium, Italy
 - Topic: Biomarkers, Imaging, Animal models - £6 million
 - 8 Projects funded – Sept 2011 - £3.7 million
- The JPND participates in the pilot European Innovation Partnership on Active and Healthy ageing
- The JPND supports the “JPIs TO CO-WORK” proposal



Next Challenges

- Publication of the SRA – January 2012
- Implementation of the SRA
 - On going discussions
 - Developing national SRA
 - Funding commitment based for the SRA on a 5 year period
 - Leverage effect
 - Based on existing mechanisms
- Scale-up funding commitment
 - For one specific call we obtained 15M€ commitment;
 - For the whole SRA, we will gather larger amounts based on country commitments accompanied by other participations (EU, Industry, stakeholders...)



National Strategic Agendas

- JPND countries have to decide how to participate on an “*a la carte*” basis to implement the European SRA.
- Levels of funding and current research capacity and expertise differ from country to country.
- In addition, most JPND countries do not have a national roadmap or identified priority actions in the field of ND research, however several countries are working towards this since deciding to participate in JPND (e.g. Italy, the Netherlands, Ireland).



Research needs and time lines

	Time to market application
Insight pathophysiology	3-20 years
Early diagnostic markers	10-15 years
Prevention strategies	15-25 years
Treatment strategies	10-20 years
Care strategies	5-10 years



Keep up to date



- Visit the JPND **website**: www.jpnd.eu
- Sign up to the JPND **News Feed**: (via the website)
- Follow us on **Twitter**: @JPNDEurope
- **E-mail us**: secretariat@jpnd.eu

